Verastem, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 6 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+14.04%
vs ±32.6% implied · ×0.43
shaded = implied · ▲▼ = realized
Verastem has 5 disclosed suppliers and 1 disclosed customer in SEC filings.
Verastem, Inc.
9.69
SentenceIn the fourth quarter of 2024, we entered into a master services agreement with IQVIA ("IQVIA Master Services Agreement") to leverage IQVIA's infrastructure and established commercialization solutions to complement our AVMAPKI FAKZYNJA CO-PACK launch strategy.
SentenceOn January 7, 2020, we entered into a license agreement with Chugai (the "Chugai Agreement") whereby Chugai granted us an exclusive worldwide license for the development, commercialization, and manufacture of products containing avutometinib.
VSTM 10-Kaccession 0001104659-26-023444
SentenceThe increase was also attributable to a $6.0 million payment made to exercise the GenFleet Option with respect to VS-7375.
VSTM 10-Kaccession 0001104659-26-023444
SentenceIn January 2025, we entered into a supply agreement with GenFleet pursuant to which GenFleet agreed to provide us with compound and licensed product for development use for VS-7375.
VSTM 10-Kaccession 0001104659-26-023444
SentencePursuant to the Secura APA, we sold to Secura our exclusive worldwide license for the research, development, commercialization, and manufacture in oncology indications of products containing duvelisib.
VSTM 10-Kaccession 0001104659-26-023444
Linked news
Expected move
Inputsspot 9.75exp Nov 20ATM strike 10ATM straddle 1.82IV 96%